Current reports
6-K
Holding(s) In Company
18 Oct 24
6-K
Holding(s) In Company
18 Oct 24
6-K
Director/pdmr Shareholding
10 Oct 24
6-K
Holding(s) In Company
4 Oct 24
6-K
Holding(s) In Company
4 Oct 24
6-K
Completion of Off-market Purchase and Total Voting
3 Oct 24
6-K
Director Declaration
3 Oct 24
6-K
Update on Purchase Alongside Pfizer Offering
1 Oct 24
6-K
Proposed Purchase Alongside Pfizer Offering
30 Sep 24
6-K
Total Voting Rights and Capital
30 Sep 24
Registration and prospectus
25-NSE
Exchange delisting
25 Mar 24
424B1
Prospectus with pricing info
19 Mar 24
424B1
Prospectus with pricing info
18 Mar 24
F-3ASR
Automatic shelf registration (foreign)
3 Jul 23
424B3
Prospectus supplement
3 May 23
424B3
Prospectus supplement
20 Apr 23
25-NSE
Exchange delisting
24 Mar 23
424B3
Prospectus supplement
24 Mar 23
POS AM
Prospectus update (post-effective amendment)
20 Mar 23
424B3
Prospectus supplement
2 Mar 23
Proxies
No filings
Other
SD
Conflict minerals disclosure
30 May 24
SD
Conflict minerals disclosure
26 May 23
EFFECT
Notice of effectiveness
24 Mar 23
CT ORDER
Confidential treatment order
19 Dec 22
CERT
Certification of approval for exchange listing
3 Nov 22
EFFECT
Notice of effectiveness
28 Oct 22
CORRESP
Correspondence with SEC
25 Oct 22
CORRESP
Correspondence with SEC
24 Oct 22
CORRESP
Correspondence with SEC
17 Oct 22
UPLOAD
Letter from SEC
17 Oct 22
Ownership
SC 13D/A
PFIZER INC
3 Oct 24
SC 13D/A
PFIZER INC
1 Oct 24
SC 13D/A
PFIZER INC
29 Jul 24
SC 13D/A
PFIZER INC
22 Mar 24
SC 13D/A
PFIZER INC
19 Mar 24
SC 13D/A
GSK plc
19 Jan 24
SC 13D/A
PFIZER INC
19 Jan 24
144
Notice of proposed sale of securities
29 Dec 23
144
Notice of proposed sale of securities
5 Dec 23
144
Notice of proposed sale of securities
3 Nov 23